Immunosuppression, Race, and Donor-Related Risk Factors Affect De novo Cancer Incidence Across Solid Organ Transplant Recipients

Mamatha Bhat, Kristin Mara, Ross Dierkhising, Kymberly D.S. Watt

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: To analyze immunosuppression regimens, demographic characteristics such as race, and donor features across solid organ transplant (SOT) recipients to provide better insight into their effect on the increased cancer risk in SOT. Patients and Methods: We analyzed the Scientific Registry of Transplant Recipients database comprising 534,472 SOT recipients across the United States from October 1, 1987, through March 31, 2015. Results: In total, 53,783 de novo malignancies were identified. Overall 15-year incidence of malignancies was 13.2% (95% CI, 13.0%-13.4%) for kidney ± pancreas, 17.9% (95% CI, 15.9%-19.8%) for pancreas alone, 15.2% (95% CI, 14.9%-15.5%) for liver, 28.1% (95% CI, 27.5%-28.7%) for heart, and 25.6% (95% CI, 24.8%-26.3%) for lung recipients. Relative to kidney ± pancreas transplant, other SOT recipients (except liver) experienced higher risk. On multivariable analysis, use of 2 or more immunosuppressant agents (P<.001), older age (P<.001), male sex (P<.001), white race (P<.001), previous malignancy (P<.001), older donor age (P=.003), and white donor race (P=.03) increased de novo malignancy, whereas mammalian target of rapamycin inhibitor use decreased risk (P=.01), driven by a reduction in skin cancer. Conclusion: Malignancy risk varies across SOT groups and correlates with the number of immunosuppressant drugs used. Mammalian target of rapamycin inhibitor–based immunosuppression seems protective against nonmelanoma skin cancer only. Cancer risk may be improved by minimizing the number of immunosuppressants and the degree of immunosuppression used, particularly in at-risk patients. Increased age, male sex, previous malignancy, and white race are characteristics that should prompt heightened vigilance in cancer screening by transplant physicians and internists who follow this patient population.

Original languageEnglish (US)
JournalMayo Clinic Proceedings
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Immunosuppression
Tissue Donors
Transplants
Incidence
Neoplasms
Immunosuppressive Agents
Pancreas
Skin Neoplasms
Sirolimus
Kidney
Transplant Recipients
Liver
Early Detection of Cancer
Registries
Demography
Databases
Physicians
Lung
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Immunosuppression, Race, and Donor-Related Risk Factors Affect De novo Cancer Incidence Across Solid Organ Transplant Recipients. / Bhat, Mamatha; Mara, Kristin; Dierkhising, Ross; Watt, Kymberly D.S.

In: Mayo Clinic Proceedings, 01.01.2018.

Research output: Contribution to journalArticle

@article{771a2198ffc6435885720ab2ffd6eb45,
title = "Immunosuppression, Race, and Donor-Related Risk Factors Affect De novo Cancer Incidence Across Solid Organ Transplant Recipients",
abstract = "Objective: To analyze immunosuppression regimens, demographic characteristics such as race, and donor features across solid organ transplant (SOT) recipients to provide better insight into their effect on the increased cancer risk in SOT. Patients and Methods: We analyzed the Scientific Registry of Transplant Recipients database comprising 534,472 SOT recipients across the United States from October 1, 1987, through March 31, 2015. Results: In total, 53,783 de novo malignancies were identified. Overall 15-year incidence of malignancies was 13.2{\%} (95{\%} CI, 13.0{\%}-13.4{\%}) for kidney ± pancreas, 17.9{\%} (95{\%} CI, 15.9{\%}-19.8{\%}) for pancreas alone, 15.2{\%} (95{\%} CI, 14.9{\%}-15.5{\%}) for liver, 28.1{\%} (95{\%} CI, 27.5{\%}-28.7{\%}) for heart, and 25.6{\%} (95{\%} CI, 24.8{\%}-26.3{\%}) for lung recipients. Relative to kidney ± pancreas transplant, other SOT recipients (except liver) experienced higher risk. On multivariable analysis, use of 2 or more immunosuppressant agents (P<.001), older age (P<.001), male sex (P<.001), white race (P<.001), previous malignancy (P<.001), older donor age (P=.003), and white donor race (P=.03) increased de novo malignancy, whereas mammalian target of rapamycin inhibitor use decreased risk (P=.01), driven by a reduction in skin cancer. Conclusion: Malignancy risk varies across SOT groups and correlates with the number of immunosuppressant drugs used. Mammalian target of rapamycin inhibitor–based immunosuppression seems protective against nonmelanoma skin cancer only. Cancer risk may be improved by minimizing the number of immunosuppressants and the degree of immunosuppression used, particularly in at-risk patients. Increased age, male sex, previous malignancy, and white race are characteristics that should prompt heightened vigilance in cancer screening by transplant physicians and internists who follow this patient population.",
author = "Mamatha Bhat and Kristin Mara and Ross Dierkhising and Watt, {Kymberly D.S.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.mayocp.2018.04.025",
language = "English (US)",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",

}

TY - JOUR

T1 - Immunosuppression, Race, and Donor-Related Risk Factors Affect De novo Cancer Incidence Across Solid Organ Transplant Recipients

AU - Bhat, Mamatha

AU - Mara, Kristin

AU - Dierkhising, Ross

AU - Watt, Kymberly D.S.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: To analyze immunosuppression regimens, demographic characteristics such as race, and donor features across solid organ transplant (SOT) recipients to provide better insight into their effect on the increased cancer risk in SOT. Patients and Methods: We analyzed the Scientific Registry of Transplant Recipients database comprising 534,472 SOT recipients across the United States from October 1, 1987, through March 31, 2015. Results: In total, 53,783 de novo malignancies were identified. Overall 15-year incidence of malignancies was 13.2% (95% CI, 13.0%-13.4%) for kidney ± pancreas, 17.9% (95% CI, 15.9%-19.8%) for pancreas alone, 15.2% (95% CI, 14.9%-15.5%) for liver, 28.1% (95% CI, 27.5%-28.7%) for heart, and 25.6% (95% CI, 24.8%-26.3%) for lung recipients. Relative to kidney ± pancreas transplant, other SOT recipients (except liver) experienced higher risk. On multivariable analysis, use of 2 or more immunosuppressant agents (P<.001), older age (P<.001), male sex (P<.001), white race (P<.001), previous malignancy (P<.001), older donor age (P=.003), and white donor race (P=.03) increased de novo malignancy, whereas mammalian target of rapamycin inhibitor use decreased risk (P=.01), driven by a reduction in skin cancer. Conclusion: Malignancy risk varies across SOT groups and correlates with the number of immunosuppressant drugs used. Mammalian target of rapamycin inhibitor–based immunosuppression seems protective against nonmelanoma skin cancer only. Cancer risk may be improved by minimizing the number of immunosuppressants and the degree of immunosuppression used, particularly in at-risk patients. Increased age, male sex, previous malignancy, and white race are characteristics that should prompt heightened vigilance in cancer screening by transplant physicians and internists who follow this patient population.

AB - Objective: To analyze immunosuppression regimens, demographic characteristics such as race, and donor features across solid organ transplant (SOT) recipients to provide better insight into their effect on the increased cancer risk in SOT. Patients and Methods: We analyzed the Scientific Registry of Transplant Recipients database comprising 534,472 SOT recipients across the United States from October 1, 1987, through March 31, 2015. Results: In total, 53,783 de novo malignancies were identified. Overall 15-year incidence of malignancies was 13.2% (95% CI, 13.0%-13.4%) for kidney ± pancreas, 17.9% (95% CI, 15.9%-19.8%) for pancreas alone, 15.2% (95% CI, 14.9%-15.5%) for liver, 28.1% (95% CI, 27.5%-28.7%) for heart, and 25.6% (95% CI, 24.8%-26.3%) for lung recipients. Relative to kidney ± pancreas transplant, other SOT recipients (except liver) experienced higher risk. On multivariable analysis, use of 2 or more immunosuppressant agents (P<.001), older age (P<.001), male sex (P<.001), white race (P<.001), previous malignancy (P<.001), older donor age (P=.003), and white donor race (P=.03) increased de novo malignancy, whereas mammalian target of rapamycin inhibitor use decreased risk (P=.01), driven by a reduction in skin cancer. Conclusion: Malignancy risk varies across SOT groups and correlates with the number of immunosuppressant drugs used. Mammalian target of rapamycin inhibitor–based immunosuppression seems protective against nonmelanoma skin cancer only. Cancer risk may be improved by minimizing the number of immunosuppressants and the degree of immunosuppression used, particularly in at-risk patients. Increased age, male sex, previous malignancy, and white race are characteristics that should prompt heightened vigilance in cancer screening by transplant physicians and internists who follow this patient population.

UR - http://www.scopus.com/inward/record.url?scp=85050542253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050542253&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2018.04.025

DO - 10.1016/j.mayocp.2018.04.025

M3 - Article

AN - SCOPUS:85050542253

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

ER -